Research & Development
We have, since our inception, set our strategic focus on major therapeutic areas with substantial unmet medical needs.
10
In-house/co-developed novel antibodies
2020
plan to file first NDA
3
NDAs to file in next 18 months
18
Clinical trials ongoing
Multiple
INDs in next 12-18 months
World Class R&D expertise
Cutting-edge antibody and cell therapy plassforms
Global clinical development capabilities
Global cGMP-compliant manufacturing capabillities
Collaborations and partnerships in China and globally
Deep China experience to drive commercial rollout
